Many obstacles to successful gene therapy remain to be overcome. Now one of them may be less imposing (pages 890–893).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yang, Y., Trinchieri, G. & Wilson, J.M. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med. 1, 890–893 (1995).
van Ginkel, F.W. et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and β-galactosidase. Hum. Gene Ther. 6, 895–903 (1995).
Yang, Y. et al. Inactivation of E2a in recombinant adenoviruses limits cellular immunity and improves the prospect for gene therapy of cystic fibrosis. Nature Genet. 7, 362–369 (1994).
Yang, Y., Li, Q., Ertl, H.C.J. & Wilson, J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004–2015 (1995).
Simon, R.H. et al. Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: Toxicity study. Hum. Gene Ther. 4, 771–780 (1993).
Zabner, J. et al. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nature Genet. 6, 75–83 (1994).
McElvaney, N.G. & Crystal, R.G. IL-6 release and airway administration of human CFTR cDNA adenovirus vector. Nature Med. 1, 182–184 (1995).
Barr, D. et al. Strain related variations in adenoviral mediated transgene expression in mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2, 151–155 (1995).
Seder, R.A. & Paul, W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 12, 635–673, 1994.
Bluestone, J.A. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2, 555–559 (1995).
Freeman, G.J. et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2, 523–532 (1995).
Clark, E.A. & Ledbetter, J.A. How B and T cells talk to each other. Nature 367, 425–428 (1994).
Foy, T.M. et al. In vivo CD40-gp39 interactions are essential for thymus-dependent immunity. II. Prolonged suppression of primary and secondary humoral immune responses by an antibody targeted to the CD40 ligand, gp39. J. exp. Med. 178, 1567–1576 (1994).
Rizzo, L.V., de Kruygg, R.H., Umetsu, D.T. & Caspi, R.R. Regulation of the interaction between Th1 and Th2 T cell clones to provide help for antibody production in vivo. Eur. J. Immunol. 25, 708–716 (1995).
McIntyre, T.M., Kehry, M.R. & Snapper, C.M. Novel in vitro model for high-rate IgA class switching. J. Immunol. 154, 3156–3161 (1995).
Kay, M.A. et al. Long-term hepatic adenovirus mediated gene expression in mice following CTLA4Ig administration. Nature Genet. (in the press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wilson, C., Kay, M. Immunomodulation to enhance gene therapy. Nat Med 1, 887–889 (1995). https://doi.org/10.1038/nm0995-887
Issue Date:
DOI: https://doi.org/10.1038/nm0995-887
This article is cited by
-
Gene therapy for cancer, the course ahead
Cancer and Metastasis Review (1996)
